Trinity Biotech Secures WHO Approval for Offshored Manufacturing of Uni-Gold HIV Test
Trinity Biotech plc has received WHO approval for offshored manufacturing of its Uni-Gold HIV rapid test. This shift to outsourced production is part of the company's financial transformation plan to improve margins, EBITDA, and cashflow, ensuring long-term growth and competitiveness.
Trinity Biotech plc has announced it has received World Health Organization (WHO) approval for the offshored and outsourced upstream manufacturing of its Uni-Gold™ HIV rapid test. This regulatory milestone allows the company to transition production from its legacy in-house operations to a more cost-effective outsourced model, while maintaining product integrity and compliance. The move is part of Trinity Biotech’s broader financial transformation plan aimed at improving gross margins, EBITDA, and cashflow, and positions the company for long-term growth and competitiveness. No other organizations are mentioned as recipients of this approval. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trinity Biotech plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-25-003934), on November 21, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
